Want to see IN:INDSWFTLAB full AI Analyst Report?
INDSWFTLAB Stock Chart & Stats
₹90.70
-₹2.17(-1.99%)
At close: 4:00 PM EST
₹90.70
-₹2.17(-1.99%)
Day’s Range― - ―
52-Week Range₹87.00 - ₹216.70
Previous CloseN/A
Volume31.71K
Average Volume (3M)7.30K
Market Cap
₹18.61B
Enterprise Value₹10.02B
Total Cash (Recent Filing)₹4.33B
Total Debt (Recent Filing)₹220.47M
Price to Earnings (P/E)39.2
Beta0.95
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)44.44
Shares Outstanding86,961,555
10 Day Avg. Volume7,859
30 Day Avg. Volume7,299
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)0.79
Price to Sales (P/S)1.71
P/FCF Ratio-10.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetLeverage fell materially versus 2021–2023 and total debt is low in 2026, strengthening solvency. A stronger balance sheet reduces refinancing and liquidity risk over the medium term, gives management flexibility for capex or strategic moves, and supports resilience against cyclical shocks.
Steady Equity GrowthConsistent equity expansion provides a deeper capital buffer and improves creditworthiness. Over 2–6 months this stability enhances access to financing, supports working capital needs and potential M&A or product investment, reducing reliance on short-term debt.
Historical Revenue & Profit UpsidePrior multi-year revenue growth and periods of solid profitability indicate the business model can scale and capture demand. This track record suggests structural capabilities—commercial execution and cost control—that can reassert once end-market conditions stabilize.
Bears Say
Negative Operating & Free Cash FlowSustained negative OCF and FCF erode liquidity and force external funding or asset sales to sustain operations. Over a multi-month horizon this raises funding risk, constrains investment in R&D or capacity, and reduces tolerance for revenue or margin shocks.
Sharp Revenue ContractionA rapid top-line decline across consecutive years implies structural demand loss, customer churn, or pricing pressure. This reduces operating leverage, pressures margins and cash generation, and makes medium-term recovery and planning more uncertain for management.
Volatile Profitability & Cash ConversionEarnings volatility combined with weak cash conversion signals lower quality of earnings and potential working-capital or one-off issues. This undermines forecasting reliability, elevates refinancing risk, and increases the likelihood of future equity or debt raises to fund operations.
Ind-Swift Laboratories Ltd. News
INDSWFTLAB FAQ
What was Ind-Swift Laboratories Ltd.’s price range in the past 12 months?
Ind-Swift Laboratories Ltd. lowest stock price was ₹87.00 and its highest was ₹216.70 in the past 12 months.
What is Ind-Swift Laboratories Ltd.’s market cap?
Ind-Swift Laboratories Ltd.’s market cap is ₹18.61B.
When is Ind-Swift Laboratories Ltd.’s upcoming earnings report date?
Ind-Swift Laboratories Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 37 days.
How were Ind-Swift Laboratories Ltd.’s earnings last quarter?
Ind-Swift Laboratories Ltd. released its earnings results on May 28, 2026. The company reported ₹1.81 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.81.
Is Ind-Swift Laboratories Ltd. overvalued?
According to Wall Street analysts Ind-Swift Laboratories Ltd.’s price is currently Overvalued.
Does Ind-Swift Laboratories Ltd. pay dividends?
Ind-Swift Laboratories Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Ind-Swift Laboratories Ltd. dividends here
What is Ind-Swift Laboratories Ltd.’s EPS estimate?
Ind-Swift Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ind-Swift Laboratories Ltd. have?
Ind-Swift Laboratories Ltd. has 86,961,555 shares outstanding.
What happened to Ind-Swift Laboratories Ltd.’s price movement after its last earnings report?
Ind-Swift Laboratories Ltd. reported an EPS of ₹1.81 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ind-Swift Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:INDSWFTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ind-Swift Laboratories Ltd.
Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, including macrolide antibiotics, cardiovascular ailments, antihistamines, antidiabetics, antipsychotics, bone resorption inhibitors, antimigraine treatments, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrhoeal/antiprotozoal conditions, anticholinergics, sedatives, hypnotics, alcohol abstinence, antineoplastics, and solutions for ADHD symptoms. Additionally, Ind-Swift supplies reference standards and impurities for a long list of specific compounds such as acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. Beyond its core manufacturing operations, the company offers a broad spectrum of services. These encompass early and late-phase drug development, process research and development, contract and API manufacturing, custom chemicals and synthesis, analytical development, regulatory support, specialized chemistry services, impurity profiling, isolation, discovery, identification, characterization, and project management. Founded in 1995, and headquartered in Manimajra, India, Ind-Swift Laboratories Limited also exports its products internationally.
Technical Analysis
Hikal Limited
―
Indoco Remedies Limited
―
Lincoln Pharmaceuticals Ltd
―
Solara Active Pharma Sciences Ltd.
―
Venus Remedies Limited
―